Andrew Goodrich

Andrew Goodrich has a diverse work experience in the field of scientific research. Andrew is currently working at EpiBiologics as a Principal Scientist I since June 2022. Prior to this, they worked at Genentech as a Scientist III from July 2020 to June 2022. Before that, they worked at Anexigen as a Scientist from September 2018 to June 2020. Andrew also has experience as a Postdoctoral Researcher at the University of Texas from January 2017 to August 2018, where they worked on developing applications of the SLAY surface display system. Additionally, they worked as a Postdoctoral Researcher and a Ph.D. Candidate at Johns Hopkins University School of Medicine, where they focused on dissecting the structure and function of nonribosomal peptide synthetases (NRPSs).

Andrew Goodrich earned a Ph.D. in Biophysics from The Johns Hopkins University School of Medicine, where they attended from 2010 to 2016. Prior to that, they completed their Bachelor of Science (B.S.) in Biochemistry at The Ohio State University, from 2006 to 2010.